Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...

Oslo, Norway, 20 September 2013 - Algeta ASA (OSE: ALGETA), announced today that Bayer has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

XOFIGO (Radium ra 223 dichloride) Injection The FDA has approved Bayer's Xofigo for the treatment of advanced prostate cancer with bone metastases. Xofigo’s safety and efficacy were evaluated in the ...

Bayer announced today that new research findings on Xofigo ® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical ...

Bayer HealthCare announced that it has begun enrolling patients into a Phase 3 trial studying Xofigo (radium Ra 223 dichloride) injection in combination with Zytiga (abiraterone acetate; Janssen) and ...

Oslo, Norway, 28 August 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the first half and second quarter 2013. A ...

"The publication of the ALSYMPCA data in the New England Journal of Medicine is important, as it will provide physicians with comprehensive data on this recently approved treatment that has ...

The market for prostate cancer treatment is $12 billion and growing, but it's getting crowded. That makes this year important as Bayer's Xofigo faces off against Johnson's Zytiga and Medivation's ...

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo ® (radium Ra 223 dichloride) for approval with a proposed indication for ...